Celyad Oncology SA CLYYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -95.93% | -91.99% | -88.33% | -21.09% | 158.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.93% | -91.99% | -88.33% | -21.09% | 158.66% |
| Cost of Revenue | -98.27% | 3.13% | 1,934.88% | 964.92% | 622.01% |
| Gross Profit | 105.62% | -283.08% | -226.80% | -231.70% | -255.58% |
| SG&A Expenses | -6.10% | 6.55% | 14.16% | -13.91% | -34.10% |
| Depreciation & Amortization | -77.50% | 31.41% | -- | -- | -- |
| Other Operating Expenses | -409.61% | -862.75% | -956.82% | -283.90% | 770.07% |
| Total Operating Expenses | -114.95% | -95.49% | -76.55% | -42.43% | -15.45% |
| Operating Income | 115.49% | 95.60% | 76.18% | 42.84% | 17.05% |
| Income Before Tax | 154.69% | 137.41% | 119.62% | 61.18% | 16.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 154.69% | 137.41% | 119.62% | 61.00% | 16.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 154.69% | 137.41% | 119.62% | 61.00% | 16.19% |
| EBIT | 115.49% | 95.60% | 76.18% | 42.84% | 17.05% |
| EBITDA | 117.68% | 98.27% | 79.13% | 44.17% | 17.58% |
| EPS Basic | 151.59% | 133.67% | 114.64% | 63.82% | 33.20% |
| Normalized Basic EPS | 114.12% | 93.18% | 72.31% | 48.39% | 33.87% |
| EPS Diluted | 142.05% | 123.36% | 103.86% | 59.81% | 33.20% |
| Normalized Diluted EPS | 109.60% | 88.29% | 67.20% | 46.50% | 33.87% |
| Average Basic Shares Outstanding | 7.30% | 3.97% | 1.98% | 8.50% | 16.18% |
| Average Diluted Shares Outstanding | 15.72% | 12.28% | 10.30% | 13.00% | 16.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |